Analyst Ratings For AcelRx Pharmaceuticals Inc (NASDAQ:ACRX)
Today, Credit Suisse Group initiated coverage on AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) with a Outperform with a price target of $7.00.
There are 7 Buy Ratings, 1 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) is Buy with a consensus target price of $8.0714 per share, a potential 234.91% upside.
Some recent analyst ratings include
- 8/5/2019-AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) has coverage initiated with a Outperform rating and $7.00 price target
- 5/9/2019-AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) had its Buy rating reiterated by LADENBURG THALM/SH SH with a $10.00 price target
- 4/24/2019-AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) has coverage initiated with a Buy ➝ Buy rating and $6.50 price target
- 12/12/2018-AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) had its Buy rating reiterated by HC Wainwright with a $9.00 price target
- 12/11/2018-AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) had its Hold rating reiterated by Oppenheimer
- On 6/5/2019 Vincent J Angotti, CEO, bought 5,000 with an average share price of $2.31 per share and the total transaction amounting to $11,550.00.
- On 3/12/2019 Mark G Edwards, Director, bought 19,000 with an average share price of $2.99 per share and the total transaction amounting to $56,810.00.
- On 2/28/2019 Pamela P Palmer, Insider, bought 840 with an average share price of $2.81 per share and the total transaction amounting to $2,360.40.
- On 2/28/2019 Raffi Asadorian, CFO, bought 3,647 with an average share price of $2.81 per share and the total transaction amounting to $10,248.07.
- On 2/28/2019 Vincent J Angotti, CEO, bought 3,234 with an average share price of $2.81 per share and the total transaction amounting to $9,087.54.
- On 12/14/2018 Raffi Asadorian, CFO, bought 5,000 with an average share price of $2.78 per share and the total transaction amounting to $13,900.00.
- On 12/14/2018 Vincent J Angotti, CEO, bought 3,610 with an average share price of $2.78 per share and the total transaction amounting to $10,035.80.
About AcelRx Pharmaceuticals Inc (NASDAQ:ACRX)
AcelRx Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain. Read More…
Recent Trading Activity for AcelRx Pharmaceuticals Inc (NASDAQ:ACRX)
Shares of AcelRx Pharmaceuticals Inc closed the previous trading session at 2.42 −0.0050 0.21% with 2.47 shares trading hands.